Interferon treatment of cirrhotic patients with chronic hepatitis C
Interferon treatment of cirrhotic patients with chronic hepatitis C
复制标题
干扰素治疗肝硬化慢性丙型肝炎患者
DOI：
10.1111/j.1365-2893.1997.tb00209.x
复制
发表时间：
1997
影响因子：
2.5
通讯作者：
D. Thiel
中科院分区：
文献类型：
--
作者：
R. Idilman;N. Maria;A. Colantoni;A. Dokmeci;D. Thiel
摘要丙型肝炎病毒（HCV）感染是目前尚未被攻克的重要传染病之一。据估计，美国有350万人患有慢性HCV。每年，这些慢性感染患者中有8000至10000人死于感染的肝脏相关并发症。有效的血液筛查检测方法的引入导致输血后HCV感染的发生率显著降低。尽管如此，重要的是要有一个慢性HCV疾病的治疗方案，防止代偿性肝硬化的发展和进展，无论是失代偿性肝硬化或肝细胞癌，因为许多人目前的医疗保健系统与慢性活动性肝炎或肝硬化。一个完全安全和有效的治疗策略慢性丙型肝炎，有或没有肝硬化，仍有待开发。在目前可用的各种治疗方案中，只有干扰素（IFN）得到了广泛的评价。干扰素治疗已被证明可以诱导肝脏炎症过程的缓解，并在某些治疗病例中消除病毒感染。因此，治疗患者的选择以及IFN治疗的剂量和持续时间仍然是有争议的问题。人们普遍认为，丙型肝炎患者对干扰素治疗无反应，对HCV感染的失代偿性丙型肝炎患者进行治疗是危险的。在这里，我们回顾了关于干扰素治疗HCV阳性肝硬化患者的现有经验，并比较了干扰素治疗慢性活动性HCV患者的应答率。
SUMMARY. Hepatitis C virus (HCV) infection is one of the more important infectious diseases yet to be conquered. An estimated 3.5 million people in the USA have chronic HCV. Each year, 8000 to 10000 of these chronically infected patients die of a liver‐related complication of their infection. The introduction of effective blood screening assays has resulted in a remarkable decrease in the incidence of post‐transfusion HCV infection. Nonetheless it is essential to have a treatment programme for chronic HCV disease that prevents the development and the progression of compensated cirrhosis to either decompensated cirrhosis or hepatocellular carcinoma, as many individuals present to the health care system with chronic active hepatitis or cirrhosis. A completely safe and effective treatment strategy for chronic HCV, with or without cirrhosis, remains to be developed. Of the various treatment alternatives currently available, only interferon (IFN) has been evaluated extensively. IFN therapy has been shown to induce remissions of the hepatic inflammatory process and also to eliminate the viral infection in some treated cases. As a result, the selection of patients for treatment and the dose and the duration of therapy with IFN are still controversial issues. It is widely held that cirrhotic individuals do not respond to IFN therapy and that treatment of decompensated cirrhotic individuals with HCV infection is dangerous. Here we review data regarding the available experience with IFN treatment of HCV‐positive individuals with cirrhosis and compare the response rates of cirrhotics to those reported for individuals with chronic active HCV.
影响因子：
29.4
作者：
OLYNYK, JK;REDDY, KR;BACON, BR
通讯作者：
BACON, BR
人成纤维细胞响应干扰素-α、干扰素-γ、白细胞介素 1 α、白细胞介素 1 β 和肿瘤坏死因子治疗而诱导重叠多肽。
DOI：
--
发表时间：
1988
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Beresini,MH;Lempert,MJ;Epstein,LB
通讯作者：
Epstein,LB